Despite the relatively non–T cell–inflamed tumor microenvironment, our group and Wang et al. have shown that patients with advanced UC with or without FGFR3 alterations respond equally well to immune checkpoint inhibition (ICI), perhaps due to a lower level of immunosuppression by stromal elements (24, 25). The gene discussed is FGFR3; the disease is neoplasm.